Eur J Pharmacol 149, 171-174, (1988). Sharkey, J., Glen, K. A., Wolfe, S., & Kuhar, M. J. View abstract in PubMed Post navigationPreviousPrevious post:The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog.NextNext post:Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems.Related PostsAnavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021Anavex Life Sciences to Present at the H.C. Wainwright Virtual BioConnect ConferenceJanuary 6, 2021Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
Anavex Life Sciences Receives Michael J. Fox Foundation Grant for Clinical Study of ANAVEX®2-73 (blarcamesine) in People with Parkinson’s DiseaseJanuary 11, 2021
Anavex Life Sciences Reports Fiscal 2020 Year End Financial Results And Clinical Program UpdatesDecember 28, 2020
Anavex Life Sciences to Announce Fiscal 2020 Year End Financial Results December 28th, 2020December 22, 2020
